Getinge (OTCMKTS:GNGBY) Announces Quarterly Earnings Results

Getinge (OTCMKTS:GNGBY) posted its quarterly earnings results on Wednesday. The company reported $0.32 earnings per share (EPS) for the quarter, Zacks reports. Getinge had a net margin of 7.81% and a return on equity of 11.12%.

Getinge Stock Performance

Shares of Getinge stock opened at $26.23 on Wednesday. Getinge has a 52 week low of $18.99 and a 52 week high of $26.23. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average price of $25.11 and a 200-day moving average price of $22.69. The company has a market cap of $7.14 billion, a PE ratio of 24.98 and a beta of 0.95.

Analyst Ratings Changes

GNGBY has been the topic of several research reports. Zacks Research downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 17th. UBS Group began coverage on shares of Getinge in a research note on Wednesday, September 2nd. They issued a “hold” rating on the stock. Pareto Securities cut shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. Finally, Nordea Equity Research downgraded shares of Getinge from a “buy” rating to a “hold” rating in a research report on Monday, August 31st. Four research analysts have rated the stock with a Hold rating. According to MarketBeat, the company has a consensus rating of “Hold”.

About Getinge

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.